Phase II Study of Nab-paclitaxel and Carboplatin Plus Bevacizumab as First-Line Chemotherapy for Reccurent or stage IIIB and IV Nonsquamous Non-Small-Cell Lung Cancer (ALCT004) - Phase II Study of Nab-PTX and CBDCA Plus Bev With Maintenance Bev As First-Line Chemotherapy for Reccurent or Advanced Non-sq NSCLC (ALCT004)

Kyorin University School of Medicine0 个研究点目标入组 33 人开始时间: 2014年3月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)SVC synd 2)Active concomitant malignancy except carcinoma in situ, intra-mucosal carcinoma or cancer with more than 5 year disease free 3)Severe active infection and sever complication (gastrointestinal hemorrhage,cardiac disease) 4)Pregnant status or lactation 5)Uncontrolled psychiatric disease 6)History of allergic reaction for agents of present treatment 7)Massive pleural effusion, peritoneal effusion or cardiac effusion required for tube drainage 8)A history of significant hemoptysis (> 2.5 mL red blood per episode) before enrolment 9)Evidence of tumor invading large vessel on imaging, cavity and thrombus 10)History of thromboembolic events.Any history of cerebral, myocardial, and pulmonary infarction 11)Symptomatic brain metastasis 12)History of operation and biopsy within 4 weeks 13)Need to antiplatelet therapy or anticoagulation therapy without Aspirin 324 mg/day within 10 days 14)Bleeding tendency, blood coagulation disorder 15)Bowel obstruction 16)Current or previous history of gastrointestinal perforation and diverticulitis 17)Pulmonary fibrosis and interstitial pneumonia on chest X-ray or symptomatic pulmonary fibrosis and interstitial pneumonia 18)Uncontrolled hypertension and diabetes 19)Other ineligible status judged by medical oncologist

发起方

Kyorin University School of Medicine